First NCFB Targeted Therapy Approval Shifts Market, Intensifies Competition

The U.S. market for Non-Cystic Fibrosis Bronchiectasis (NCFB) is entering a new phase of targeted treatments following the FDA approval of Insmed's Brinsupri on August 12, 2025. This marks the first specific therapy addressing underlying disease mechanisms, shifting the treatment paradigm from supportive care and symptom management to directly tackling neutrophilic inflammation, chronic infection, and recurrent pulmonary exacerbations.

Brinsupri's approval validates Dipeptidyl Peptidase 1 (DPP1) inhibition as a commercially viable mechanism for NCFB. Insmed reported substantial revenue for Brinsupri, with $172.7 million in 2025 and significant growth continuing into 2026, indicating strong patient and physician adoption for exacerbation prevention.

Industry competition is poised to escalate. Boehringer Ingelheim and Chiesi–Haisco are advancing late-stage DPP1 inhibitor programs, while other companies are developing alternative approaches, including PDE3/PDE4 inhibitors, inhaled immunoglobulins, and bacteriophage therapies. Future market leadership will likely hinge on demonstrating superior efficacy in reducing exacerbations, preserving lung function, and ensuring long-term safety and convenience.

NCFB is a chronic respiratory condition characterized by irreversible airway damage, leading to recurrent infections and persistent inflammation. Affecting an estimated 500,000 individuals in the United States, the disease landscape is evolving rapidly with the introduction of mechanism-based therapies.